论文部分内容阅读
法莫替丁(Famotidine)为治疗溃疡病新药,由日本山之内制药株式会社开发,并于1985年7月首次上市。该药的最大特点是:1.拮抗胃粘膜壁细胞的组胺 H_2受体,具有强大而持久的抑制胃酸分泌作用;2.安全范围大,用药剂量小;3.无抗雄激素作用及抑制药物代谢酶的作用。药理试验证明,法莫替丁的 H_2受体拮抗作用比西米替丁(Cimetidine)强10～148倍。对组织胺刺激胃酸分泌的抑制作用(狗),比西米替丁强约40倍,持续时间长
Famotidine, a new drug for the treatment of ulcer disease, was developed by Japan’s Yamanouchi Pharmaceutical Co., Ltd. and was first introduced in July 1985. The drug’s most important features are: 1. antagonism of gastric mucosal parietal cells histamine H 2 receptors, with a strong and lasting inhibition of gastric acid secretion; 2. safety range, the dosage is small; 3. anti-androgen-free and inhibitory The role of drug metabolizing enzymes. Pharmacological tests show that famotidine H 2 receptor antagonistic effect than cimetidine (Cimetidine) 10 to 148 times stronger. Inhibition of histamine stimulation of gastric acid secretion (dog), about 40 times stronger than cimetidine, long duration